+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CNS Lymphoma Drug"

Central Nervous System Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

Central Nervous System Lymphoma - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
CNS Lymphoma - Pipeline Insight, 2024 - Product Thumbnail Image

CNS Lymphoma - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
From
CNS Lymphoma - Epidemiology Forecast - 2032 - Product Thumbnail Image

CNS Lymphoma - Epidemiology Forecast - 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
From
From
  • 9 Results (Page 1 of 1)
Loading Indicator

The CNS Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. It is composed of drugs used to treat central nervous system (CNS) lymphoma, a rare type of cancer that affects the brain and spinal cord. These drugs are typically used in combination with other treatments such as radiation and chemotherapy. Commonly used CNS Lymphoma Drugs include rituximab, bendamustine, and temozolomide. The CNS Lymphoma Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Roche, Novartis, Merck, Pfizer, and Bristol-Myers Squibb. Other companies such as Celgene, Gilead, and AbbVie are also active in the market. Show Less Read more